Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 1/20 | 0.76 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.76 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.76 |
| ▸ | LDHA | P00338 | 1/20 | 0.76 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.76 |
| ▸ | FBP1 | P09467 | 1/20 | 0.76 |
| ▸ | SRC | P12931 | 1/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.76 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.76 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.76 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.76 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.76 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.76 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.76 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26067730 | 1.00 | DNPH1 (0.76) | DNPH1PRKAB2TRPM2LDHAADRB2 | |
| SCHEMBL20282954 | 0.93 | DNPH1 (0.76) | DNPH1PRKAB2TRPM2LDHAADRB2 | |
| SCHEMBL31547790 | 0.92 | P2RY1 (0.64) | DNPH1PRKAB2TRPM2LDHAADRB2 | |
| SCHEMBL25390508 | 0.92 | P2RY1 (0.80) | DNPH1PRKAB2TRPM2LDHAADRB2 | |
| SCHEMBL29438526 | 0.92 | P2RY1 (0.80) | DNPH1PRKAB2TRPM2LDHAADRB2 | |
| SCHEMBL2483380 | 0.92 | P2RY1 (0.80) | DNPH1PRKAB2TRPM2LDHAADRB2 | |
| SCHEMBL599965 | 0.92 | P2RY1 (0.80) | DNPH1PRKAB2TRPM2LDHAADRB2 | |
| SCHEMBL20282955 | 0.91 | DNPH1 (0.73) | DNPH1PRKAB2TRPM2LDHAADRB2 | |
| SCHEMBL21999787 | 0.91 | ADORA1 (0.61) | DNPH1PRKAB2TRPM2LDHAADRB2 | |
| SCHEMBL20673286 | 0.90 | DNPH1 (0.72) | DNPH1PRKAB2TRPM2LDHAADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | BANK OF AMERICA, N.A. | 2025-04-17 | — | — | US | disclosed |
| US-11028392-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3693463-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | Alnylam Pharmaceuticals, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3052628-B1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190144870-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | BANK OF AMERICA, N.A. | 2019-05-16 | — | — | US | disclosed |
| US-10119143-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-20160244766-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-6340754-B1 | ANTISENSE AGENTS AND PHOSPHODIESTERSES | NOVARTIS AG (CH) | 2002-01-22 | — | — | US | disclosed |
| US-6147211-A | BIOCATALYTIC HYDROLYSIS OF A 2'-DERIVATIZED CYCLIC PHOSPHATE NUCLEOTIDE WITH A CYCLIC PHOSPHODIESTERASE TO YIELD THE CORRESPONDING 2'-DERIVATIZED NUCLEOSIDE USEFUL AS ANTISENSE AGENT | NOVARTIS AG (CH) | 2000-11-14 | — | — | US | disclosed |
| WO-2000020429-A1 | 3',5'-CYCLIC PHOSPHATE COMPOUNDS AND METHODS THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244766-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | DNPH1 2835/4885PRKAB2 1499/4885TRPM2 4052/4885 |
| US-11028392-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | AARS1, RNASE1, DDX39B | DNPH1 2835/4885PRKAB2 1499/4885TRPM2 4052/4885 |
| US-20190144870-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | DNPH1 2835/4885PRKAB2 1499/4885TRPM2 4052/4885 |
| US-10119143-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | AARS1, RNASE1, DDX39B | DNPH1 2835/4885PRKAB2 1499/4885TRPM2 4052/4885 |
| US-20250122505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | DNPH1 2835/4885PRKAB2 1499/4885TRPM2 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.